TCT-765 Effect of PSP and other Elements of Technique on 3 Year Outcomes Among Metallic Everolimus-Eluting Stent-Treated Patients in the ABSORB Trials

Abstract

In the ABSORB randomized trials, XIENCE cobalt-chromium everolimus-eluting stents (EES) resulted in lower rates of target lesion failure (TLF) and device thrombosis through 3 years compared with Absorb BVS. For BVS implantation, data has supported improved outcomes with PSP technique (e.g. pre-